All In MedTech

Device Trial Radar · NCT00295802

Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

Last checked: Nov 21, 2026Latest source record: Feb 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

141

Actual

Start

Apr 2006

Primary completion

Aug 2012

Study completion Sep 2014

Sponsor

Lead sponsor
EDAP TMS S.A.Not on our public-company list
Sponsor type
Industry
First posted
Feb 24, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the substantial equivalence of the Ablatherm high intensity focused ultrasound (HIFU) as compared to cryotherapy for the treatment of low risk, localized prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • Integrated Imaging High Intensity Focused UltrasoundDevice

  • Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)Device

    Cryotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsyTime frame: Through 24 month period

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Chinn & Chinn Urology Associates

    Arcadia, California

14 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.